Autonomix Medical, Inc.

Autonomix Medical, Inc.

Autonomix Medical is a medical-device firm focused on treating chronic pain through peripheral nerve ablation. It was founded by a team with backgrounds in interventional pain management and medical device engineering. The company's core technology uses a proprietary catheter to deliver radiofrequency energy to targeted nerves. The company's strategy involves advancing its system through FDA clinical trials. Its lead indication is pain from pancreatic cancer, a condition with high unmet need. Autonomix also explores applications in peripheral artery disease and other pain syndromes. The firm has raised venture funding from investors including Santé Ventures. Autonomix Medical operates as a development-stage company, with no approved products or revenue as of 2025. It employs fewer than 50 professionals. The firm has conducted pre-clinical studies and early feasibility trials in the United States. Autonomix Medical distinguishes itself by targeting a specific anatomical and clinical niche: treating visceral pain via the celiac plexus. This approach may offer a less invasive alternative to traditional surgical or pharmacological interventions. The firm's regulatory pathway remains early, with FDA clearance not yet achieved.